Role of Serum Uric Acid as a Protective Biomarker in Patients with Different Histopathological Grades of Oral Squamous Cell Carcinoma: a Case-Control Study

Soheila Manifar,1 Arezoo Rahimzamani,2 Mohammad Shirkhoda,3 Mohammad Nikkhah Ghamsari,4 and Mahin Bakhshi2

1Department of Oral Medicine, School of Dentistry, Tehran University of Medical Sciences, Imam Khomeini Hospital Complex, Tehran, Iran
2Department of Oral Medicine, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Department of Surgery, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
4Dentist, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence should be addressed to Mahin Bakhshi; mahinbakhshi@yahoo.com

Received 12 June 2020; Revised 16 August 2020; Accepted 6 September 2020; Published 14 September 2020

The antioxidant properties of uric acid may have a protective effect against the formation of oxygen radicals and subsequently against carcinogenicity. The present study aimed at evaluating the serum level of uric acid in patients with oral squamous cell carcinoma (OSCC) with different histopathological grades. In this descriptive-analytical, case-control study, patients with OSCC and healthy controls were selected and matched regarding age and gender. The serum samples were collected from patients (before radiotherapy and chemotherapy) and controls, and their serum uric acid levels were measured enzymatically. Data were analyzed using independent t-test and ANOVA at 0.05 level of significance. The mean serum uric acid level in OSCC patients (4.2 ± 1.5 mg/dL) and healthy controls (4.38 ± 1.22 mg/dL) was not significantly different (P = 0.377). No significant association was noted between the histopathological grade of OSCC and mean serum uric acid (P = 0.781). The serum uric acid level had a direct significant correlation with age in OSCC patients (P < 0.001). The results of this study did not support the role of uric acid as a protective biomarker in OSCC. Further prospective studies are recommended to better elucidate the role of uric acid in the etiology of OSCC.

1. Introduction

In recent years, cancer has been one of the leading causes of mortality in human societies. It is the second most common cause of death after cardiovascular diseases in the United States [1, 2] and the third most common cause of death in Iran [3]. Oral cancer is among the most common cancers worldwide and is a public health dilemma. According to histopathological examinations, squamous cells are the origin of nearly 90% of oral cancers, referred to as oral squamous cell carcinoma (OSCC) [4].

Oxidative stress is one of the indicators of cancer development, resulting from an imbalance between the levels of oxidative and antioxidant agents in biological systems. Many of the oxidative stress biomarkers produced by oxygen free radicals are involved in the pathogenesis of many diseases, including cancer [5].

Uric acid is the final enzymatic product of the breakdown of purine nucleotides and free bases in the human body [6]. According to some previous studies, a reduction in serum uric acid level has been associated with an increase in the risk of lung cancer, oral cancer, and laryngeal cancer [7–10]. However, some others have reported that uric acid plays a role as a prooxidant under conditions of oxidative stress through reactions with nitric oxide and impairs the vascular epithelial function and leads to the occurrence of systemic diseases [9–14].
Uric acid appears to elicit an antioxidant defense mechanism against oxidative stress and the aging processes caused by free radicals that are also associated with DNA damage, attachment, migration, proliferation, and regulation of tumor cells, and mortality. On the other hand, the degradation of tumor cells may increase the serum uric acid level, which stimulates the immune system (CD8⁺ T-lymphocytes in particular) and enhances the defense mechanisms against cancer by inducing cytotoxic cell death and inhibiting the proliferation and migration of tumor cells. These findings support the positive association of serum uric acid level and survival in patients with colon cancer and nasopharyngeal carcinoma [15]. In contrast, elevated serum uric acid levels are inversely correlated with low adiponectin levels, and low adiponectin levels may overactivate the phosphorylation of PI3K/Akt (phosphoinositide 3-kinase/B kinase protein) and signaling pathways and eventually lead to an increase in the proliferation of tumor cells [13]. Given the paradoxical role of uric acid as an antioxidant and prooxidant in the occurrence of OSCC, the aim of the present study was to evaluate the serum uric acid level in a group of patients with OSCC.

2. Materials and Methods

2.1. Primary Outcome Measures. The main objectives of this study were (I) to compare the mean serum level of uric acid between OSCC patients and healthy controls and (II) to compare the mean serum level of uric acid in OSCC patients with different histopathological grades.

2.2. Study Design. This descriptive-analytical, case-control study was performed on newly diagnosed patients with OSCC, confirmed by a pathologist at Imam Khomeini Cancer Institute in Tehran. The patients were selected by convenience sampling.

2.3. Participants. Forty newly diagnosed patients with OSCC were selected. The patients had definite histopathological diagnosis of OSCC according to their pathology report. The inclusion criterion for OSCC patients was (I) patients whose diagnosis of OSCC had been confirmed histopathologically. The exclusion criteria were (I) initiation of treatment (radiotherapy and/or chemotherapy), (II) systemic diseases such as rheumatoid arthritis, type II diabetes, obesity, hypertension, cardiovascular diseases, renal failure, and gout due to decreased level of nitric oxide and vascular epithelial malfunction as a result of high level of uric acid [14, 16].

Healthy controls were selected among healthy individuals who had presented for regular check-up and had no systemic conditions. The control group matched the patient group in terms of age and gender.

2.4. Data Collection. The patients’ information was recorded in a checklist anonymously and included gender, age, histopathological grade of tumor, location of tumoral lesion, and uric acid level.

For OSCC patients, the histopathological grade of OSCC was extracted from their pathology report. The classification system used for grading was as follows [17]:

| Grade | Description                       |
|-------|-----------------------------------|
| G1    | Well differentiated (low grade)   |
| G2    | Moderately differentiated (intermediate grade) |
| G3    | Poorly differentiated (high grade) |
| G4    | Undifferentiated (high grade)     |

After obtaining written informed consent from the participants, blood samples (5 cc) were collected from the radial vein of patients and healthy controls during 8-10 a.m. The serum level of uric acid was measured using a uric acid assay kit (Bionik, Germany), which enzymatically measures the serum uric acid at 520 nm wavelength. According to the information provided in the kit, the normal mean serum level of uric acid is 3.5-7.2 mg/dL in males and 2-6 mg/dL in females.

2.5. Statistical Analyses. The minimum sample size was calculated to be 37 in each group according to a previous study by Ara et al. [18], assuming 1.5-unit difference between the two groups, alpha = 0.05, study power of 0.8, and standard deviation of 2.3.

Data were analyzed using SPSS version 22 (SPSS Inc., IL, USA). The Kolmogorov-Smirnov test was used to evaluate the distribution of data. Independent t-test, ANOVA, and Pearson’s correlation coefficient were used for data analysis. The level of significance was set at 0.05.

We used a 95% confidence interval for this study. In other words, we predicted a 5% probability of errors in the results. No bias was found in this study.

3. Results

3.1. Characteristics of the Participants. Of a total of 80 participants, 40 were males (n = 20 in each group) and 40 were females (n = 20 in each group) (P = 1).

The mean age of patients was 46.86 ± 9.66 years (range 26-66 years), and the mean age of healthy controls was 47.3 ± 8.76 years (range 31-66 years). According to the Kolmogorov-Smirnov test, data regarding the age of the two groups were normally distributed. Thus, the student t-test was applied to compare the two groups regarding age, which revealed no significant difference (P = 0.2).

The frequency of lesions according to their location in the oral cavity was also studied. The tongue was the most common location for the occurrence of OSCC.

Of 40 patients who participated in this study, the grade of OSCC was mild in 18 (22.5%), moderate in 14 (17.5%), and high in 8 (10%) patients. We did not have any grade 4 cases.

Table 1 presents the gender and age of patients, location of OSCC lesions, and histopathological tumor grade.

Table 2 and 3 shows the frequency of OSCC lesions in different locations in the oral cavity according to their histopathological grade.

3.2. Assessment of the Serum Uric Acid Level. Table 3 shows the mean serum uric acid level in the patient and control groups. The Kolmogorov-Smirnov test confirmed the normal distribution of serum uric acid level data in the patient and control groups (P = 0.2). Thus, t-test was used to compare the mean serum uric acid level between the two groups,
which revealed no statistically significant difference in this respect \((P = 0.377)\).

Table 4 shows the mean serum level of uric acid in male and female patients. The Kolmogorov-Smirnov test confirmed the normal distribution of serum uric acid data in male and female patients. Thus, \(t\)-test was used to compare the mean serum uric acid level between males and females, which showed no significant difference \((P = 0.201)\).

Since the data regarding age and serum uric acid level were normally distributed, the Pearson’s correlation coeffi-
In another study in Austria, Strasak et al. [29] found that higher serum level of uric acid was associated with a higher risk of mortality, although they did not observe a correlation between the serum uric acid level and cancer incidence. Yuan et al. [30] suggested that serum uric acid level could be a good marker for the evaluation of tumor metastasis. Therefore, serum uric acid level may be a good predictor for metastasis in patients with rectal cancer. They found that serum uric acid concentration was correlated with the presence of C-reactive protein and carcinoembryonic antigen in patients with rectal cancer. They concluded that any increment in uric acid levels would be a strong correlation between the serum uric acid levels and stages of malignancy in gastric cancer patients. They found that increased uric acid levels would be followed by an increase in stages of malignancy in gastric cancer.

Lea [32] in an observational analytical study in Indonesia found a strong correlation between the serum uric acid levels and stages of malignancy in gastric cancer patients. They concluded that any increment in uric acid levels would be followed by an increase in stages of malignancy in gastric cancer. They found that the mean salivary levels of uric acid, glutathione S transferase, and superoxide dismutase in OSCC patients were statistically significant lower compared with healthy controls, and glutathione S transferase and superoxide dismutase levels were not significantly different based on clinical stages; whereas, the uric acid level showed a progressive reduction from stage I to stage IV, although this reduction was not statistically significant.

The current study had some limitations such as small sample size and diet as a confounding factor. The results of this study did not support the role of uric acid as a protective biomarker in different grades of OSCC. No significant relationship was found between the histopathological grade and the serum level of uric acid either. Future multicenter or cohort studies with a larger sample size are required to further elucidate this topic.

### Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

### Ethical Approval

This study was approved by the Research Committee in the Dental Faculty, Shahid Beheshti University of Medical Sciences, Tehran, Iran (ethical number: IR.SBMU.RIDS.REC.1395.428).

### Conflicts of Interest

The authors declare that there is no conflict of interests regarding the publication of this paper.

### Acknowledgments

The authors would like to appreciate the laboratory staff at Imam Khomeini Hospital Complex, Tehran, Iran.

### References

[1] B. W. Neville, D. D. Damm, C. M. Allen, and A. C. Chi, *Oral and Maxillofacial Pathology: Elsevier Health Sciences, Elsevier Health Sciences*, 2015.

[2] K. Vinay, A. K. Abbas, N. Fauston, and J. J. S. Aster, *Robbins and Cotran Pathologic Basis of Disease*, Elsevier, China, 2005.

[3] S. M. Mousavi, M. M. Gouya, R. Ramazani, M. Davanlou, N. Hajsadeghi, and Z. Seddighi, “Cancer incidence and mortality in Iran,” *Annals of Oncology: official journal of the European Society for Medical Oncology*, vol. 20, no. 3, pp. 556–563, 2009.

[4] M. Cristaldi, R. Maucri, O. di Fede, G. Giuliani, G. Campisi, and V. Panzarella, “Salivary biomarkers for oral squamous cell carcinoma diagnosis and follow-up: current status and perspectives,” *Frontiers in Physiology*, vol. 10, 2019.

[5] H. Maier, H. Weidauer, J. Zoller et al., “Effect of chronic alcohol consumption on the morphology of the oral mucosa,” *Alcoholism, Clinical and Experimental Research*, vol. 18, no. 2, pp. 387–391, 1994.

[6] M. Khoumsabjafar, K. Ansarin, and A. Jouyban, “Salivary malondialdehyde as an oxidative stress biomarker in oral and systemic diseases,” *Journal of Dental Research, Dental Clinics, Dental Prospects*, vol. 10, no. 2, pp. 71–74, 2016.

[7] N. Kuzkaya, N. Weissmann, D. G. Harrison, and S. Dikalov, “Interactions of peroxynitrite with uric acid in the presence
of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase,” *Biochemical Pharmacology*, vol. 70, no. 3, pp. 343–354, 2005.

[8] C.-Y. Hsu, M. Shao, W. Cao, S. Li, and L. Zhou, “Pretreatment serum uric acid as an efficient predictor of prognosis in men with laryngeal squamous cell cancer: a retrospective cohort study,” *Oxidative Medicine and Cellular Longevity*, vol. 2019, Article ID 1821969, 12 pages, 2019.

[9] M. Bagnati, C. Perugini, C. Cau, R. Bordone, E. Albano, and G. Bellomo, “When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid,” *Biochemical Journal*, vol. 340, no. 1, pp. 143–152, 1999.

[10] S. M. Sanguinetti, C. Batthyány, A. Trostchansky et al., “Nitric oxide inhibits prooxidant actions of uric acid during copper-mediated LDL oxidation,” *Archives of Biochemistry and Biophysics*, vol. 423, no. 2, pp. 302–308, 2004.

[11] K. Kittridge and R. L. Willson, “Uric acid substantially enhances the free radical-induced inactivation of alcohol dehydrogenase,” *FEBS Letters*, vol. 170, no. 1, pp. 162–164, 1984.

[12] A. S. Zarrini, D. Moslemi, H. Parsian, A. Mosapour, and Z. S. Kelgari, “The status of antioxidants, malondialdehyde and some trace elements in serum of patients with breast cancer,” *Caspian Journal of Internal Medicine*, vol. 7, no. 1, pp. 31–36, 2016.

[13] Y. Y. Sautin and R. J. N. Johnson, “Uric acid: the oxidant-antioxidant paradox,” *Nucleosides, Nucleotides and Nucleic Acids*, vol. 27, no. 6-7, pp. 608–619, 2008.

[14] R. Salzman, L. Pacal, J. Tomandl et al., “Elevated malondialdehyde correlates with the extent of primary tumor and predicts poor prognosis of oropharyngeal cancer,” *Anticancer Research*, vol. 29, no. 10, pp. 4227–4231, 2009.

[15] Y. F. Chen, Q. Li, D. T. Chen et al., “Prognostic value of preoperative serum uric acid levels in esophageal squamous cell carcinoma patients who undergo R0 esophagectomy,” *Cancer Biomarkers*, vol. 17, no. 1, pp. 89–96, 2016.

[16] L. N. Kolonel, C. Yoshizawa, A. Nomura, and G. N. Stemmermann, “Relationship of serum uric acid to cancer occurrence in a prospective male cohort,” *Cancer Epidemiology and Prevention Biomarkers*, vol. 3, no. 3, pp. 225–228, 1994.

[17] V. P. Wagner, L. P. Webber, M. Curra et al., “Bryne’s grading system predicts poor disease-specific survival of oral squamous cell carcinoma: a comparative study among different histologic grading systems,” *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*, vol. 123, no. 6, pp. 688–696, 2017.

[18] S. A. Ara, S. Ashraf, and B. M. Patil, “Evaluation of serum uric acid levels in patients with oral squamous cell carcinoma,” *Indian Journal of Dental Research*, vol. 27, no. 2, p. 178, 2016.

[19] X. W. Wu, D. M. Muzny, C. Chi Lee, and C. Thomas Caskey, “Two independent mutational events in the loss of urate oxidase during hominoid evolution,” *Journal of Molecular Evolution*, vol. 34, no. 1, pp. 78–84, 1992.

[20] K. M. Robinson, J. T. Morre, and J. S. Beckman, “Triuret: a novel product of peroxy nitrite-mediated oxidation of urate,” *Archives of Biochemistry and Biophysics*, vol. 423, no. 1, pp. 213–217, 2004.

[21] B. N. Ames, R. Cathcart, E. Schwiers, and P. Hochstein, “Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 78, no. 11, pp. 6858–6862, 1981.

[22] R. Kand’ar, P. Zakova, and V. Muzakova, “Monitoring of antioxidant properties of uric acid in humans for a consideration measuring of levels of allantoin in plasma by liquid chromatography,” *Clinica Chimica Acta*, vol. 365, no. 1–2, pp. 249–256, 2006.

[23] A. Lawal, B. Kolude, and B. F. Adeyemi, “Serum uric acid levels in oral cancer patients seen at tertiary institution in Nigeria,” *Annals of Ibadan Postgraduate Medicine*, vol. 10, no. 1, pp. 9–12, 2012.

[24] J. Giebultowicz, P. Wroczynski, and D. Samolczyk-Wanyura, “Comparison of antioxidant enzymes activity and the concentration of uric acid in the saliva of patients with oral cavity cancer, odontogenic cysts and healthy subjects,” *Journal of Oral Pathology & Medicine*, vol. 40, no. 9, pp. 762–730, 2011.

[25] R. A. Hiatt and B. H. Fireman, “Serum uric acid unrelated to cancer incidence in humans,” *Cancer Research*, vol. 48, no. 10, pp. 2916–2918, 1988.

[26] G. Almadori, F. Busso, J. Galli et al., “Salivary glutathione and uric acid levels in patients with head and neck squamous cell carcinoma,” *Journal for the Sciences and Specialties of the Head and Neck*, vol. 29, no. 7, pp. 648–654, 2007.

[27] A. Roi, L. C. Rusu, C. I. Roi, R. E. Luca, S. Boia, and R. I. Munteanu, “A new approach for the diagnosis of systemic and oral diseases based on salivary biomolecules,” *Disease Markers*, vol. 2019, Article ID 8761860, 11 pages, 2019.

[28] V. Salian, F. Demeri, and S. Kumari, “Estimation of salivary nitric oxide and uric acid levels in oral squamous cell carcinoma and healthy controls,” *Clinical Cancer Investigation Journal*, vol. 4, no. 4, p. 516, 2015.

[29] A. Strasak, K. Rapp, W. Hilde et al., “The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28,000 older Austrian women,” *Annals of Oncology*, vol. 18, no. 11, pp. 1893–1897, 2007.

[30] C. Yuan, X.-H. Xu, X.-L. Wang, L. Xu, Z. Chen, and Y.-Q. Li, “Relationship between serum uric acid and metastatic and nonmetastatic rectal cancer patients with undergoing no chemotherapy,” *Medicine*, vol. 95, no. 47, p. e5463, 2016.

[31] A. Yiu, M. van Hemelrijck, H. Garmo et al., “Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study,” *Oncotarget*, vol. 8, no. 26, p. 42332, 2017.

[32] K. Y. Lea, “The correlation between uric acid and stages of malignancy among gastric cancer patient in Palembang, Indonesia,” in *Journal of Physics: Conference Series*, IOP Publishing, 2019.

[33] H. Singh, P. Shetty, V. S. S, and M. Patidar, “Analysis of salivary antioxidant levels in different clinical staging and histological grading of oral squamous cell carcinoma: noninvasive technique in dentistry,” *Journal of clinical and diagnostic research: JCDR*, vol. 8, no. 8, pp. ZC08–ZC11, 2014.